New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
05:43 EDTOMEDOncoMed recent pullback a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the recent pullback in shares of OncoMed following the FDA's partial clinical hold on vantictumab as a buying opportunity. Piper wants to own shares ahead of the company's data read-outs in the second half of 2014. It reiterates an Overweight rating on the stock with a $43 price target.
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 13, 2015
05:52 EDTOMEDOncoMed pipeline 'dramatically' undervalued, says Piper Jaffray
Following the company's Q4 results, Piper Jaffray says it views OncoMed's clinical pipeline as "dramatically" undervalued. Piper notes the company ended 2014 with $232M in cash and guided to end 2015 with greater than $120M. It reiterates an Overweight rating on the stock with a $43 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use